Trial Profile
A study of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2018 Results published in the Advances in Therapy
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium